Autopsy report · NCT03846128
Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer
Cause of deathOther
“Changes in the indication for Sunitinib in metastatic renal cell carcinoma, which have led to a significant decrease in its use in the urology department. Collected data will not be sufficient to perform a statistical analysis.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 2 years 4 months before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- University Hospital, Rouen
- Sponsor type
- University, hospital or other
- Conditions
- Metastatic Kidney Cancer
- Interventions
- blood sample
- Participants
- 6
- Sites
- 1
- Countries
- France
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.